The IPKat

Showing posts with the label economics of pharmaceutical IP

View all

Posts

Not just any old IPKat ...

2026

“Most Popular Intellectual Property Law Blawg” of all time according to Justia rankings, October 2026.

2026

“Most Popular Copyright Blawg” of all time according to Justia rankings, October 2026.

2025

“Best UK Intellectual Property blog” of all time according to FeedSpot, May 2025.

2024

PermaKat Eleonora Rosati has been quoted, and the IPKat has also been hyperlinked in The New York Times, April 2024.

2023

PermaKat Eleonora Rosati and The IPKat are expressly recommended as sources to follow to get an “unstuffy look at IP issues” according to Legal Business, April 2023.

View all recognitions ↓ Show less ↑

2022

PermaKat Eleonora Rosati received the 2022 Adepi Award.

2020

PermaKat Eleonora Rosati was listed as one of World Intellectual Property Review’s “Influential Women in IP”.

2018

PermaKat Eleonora Rosati was listed as one of Managing Intellectual Property magazine’s “Fifty Most Influential People”.

2005–14

IPKat founder and Blogmeister Emeritus Jeremy Phillips was listed as one of Managing Intellectual Property magazine’s “Fifty Most Influential People” in 2005, 2011, 2013 and 2014.

2013

Recommended by the European Patent Office as reading material for candidates for the European Qualifying Examinations.

2011

Listed as “Top Legal Blog” in The Times Online, March 2011.

2010

One of the only two non-US blogs listed in the 2010 ABA Journal Blawg 100.

2010

Number 1 in the 2010 Top Copyright Blog list compiled by the Copyright Litigation Blog, July 2010.

2010

Selected by the United States Library of Congress for inclusion in its historic collections of Internet materials related to Legal Blawgs.

2009

Top Patent Blog poll: 3rd out of 50 (“Favourite Patent Blog”) and 2nd out of 50 (“Most-read”).

2008

ComputerWeekly IT Law and Governance Blog of the Year, 20 August 2008.

2008

Best of the Blogs, Times Online, 21 August 2008.

↑

The IPKat

Buscar este blog

Posts

Does the economic impact of SPCs necessitate SPC Regulation reform? The European Commission wants to find out

Letter from AmeriKat: Will narrowing innovator-generic price gap change IP law?

Letter from AmeriKat: Brought to you by the Letters 'A', 'W' and 'R' and the numbers 50 million and $100 million

Katonomics 6: the Economics of IP in Pharmaceuticals